A Phase IIIb, Multicentre, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan) in Phenylketonuria (PKU) Patients <4 Years Old
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 May 2017
At a glance
- Drugs Sapropterin (Primary)
- Indications Phenylketonuria
- Focus Therapeutic Use
- Acronyms SPARK
- Sponsors BioMarin Pharmaceutical; Merck KGaA
- 03 May 2017 This trial has been completed in Netherlands.
- 28 Mar 2017 This trial has been completed in Germany (End date:2017-02-17), as per European Clinical Trials Database record.
- 09 Mar 2017 This trial has been completed in Italy, as per European Clinical Trials Database record.